Search

Your search keyword '"Letarouilly, Jean-Guillaume"' showing total 164 results
Start Over Author "Letarouilly, Jean-Guillaume"
164 results on '"Letarouilly, Jean-Guillaume"'

1. Évaluation globale standardisée systématique des rhumatismes inflammatoires chroniques : intérêts et limites

Author

Fogel, Olivier, Caillet-Portillo, Damien, Najm, Aurélie, Baillet, Athan, Claudepierre, Pascal, Conort, Ornella, Dernis, Emmanuelle, Fayet, Françoise, Gossec, Laure, Goupille, Philippe, Hudry, Christophe, Letarouilly, Jean-Guillaume, Lukas, Cédric, Marotte, Hubert, Molto, Anna, Pouplin, Sophie, Senbel, Eric, Sordet, Christelle, Tournadre, Anne, Truchetet, Marie-Elise, Wendling, Daniel, Ruyssen-Witrand, Adeline, and Dougados, Maxime

Published
2025
Full Text
View/download PDF

2. Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative

Author

Ruyssen-Witrand, Adeline, Caillet-Portillo, Damien, Najm, Aurélie, Fogel, Olivier, Baillet, Athan, Claudepierre, Pascal, Conort, Orenella, Dernis, Emmanuelle, Fayet, Françoise, Gossec, Laure, Goupille, Philippe, Hudry, Christophe, Letarouilly, Jean-Guillaume, Lukas, Cédric, Marotte, Hubert, Molto, Anna, Pouplin, Sophie, Senbel, Eric, Sordet, Christelle, Tournadre, Anne, Truchetet, Marie-Elise, Wendling, Daniel, and Dougados, Maxime

Published
2024
Full Text
View/download PDF

7. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study

Author

AUDEMARD-VERGER, Alexandra, AZZI, Emmanuel, BANNEVILLE, Béatrice, BAUDET, Antoine, BEAUDOUIN BAZIRE, Constance, BELIZNA, Cristina, Belot, Alexandre, BENHAMOU, Ygal, Berezné, Alice, BERNARD-GUERVILLY, Fanny, BERTHIER, Sabine, BEZANAHARY, Holy, BIALE, Lisa, BIGOT, Adrien, BLANCHARD-DELAUNAY, Claire, CALAS, Anne, CAMPAGNE, Julien, CATHEBRAS, Pascal, CAZALETS, Claire, CHAIGNE, Benjamin, CHANDESRIS, Olivia, CHATELAIS, Jérémy, CHATELUS, Emmanuel, COHEN, Fleur, Combe, Bernard, COMPARON, Céline, COQUERELLE, Pascal, DAMIAN, Louise, DAUGAS, Eric, DE MENTHON, Mathilde, DE MOREUIL, Claire, DELATTRE, Estelle, DELLAL, Azeddine, Deneux-Tharaux, Catherine, DENIS, Amélie, DEPROUW, Camille, DERNIS, Emmanuelle, DEROUX, Alban, DESOUCHES, Sandra, Dieudé, Philippe, DIREZ, Guillaume, Dougados, Maxime, DRIESSEN, Marine, DU THANH, Aurélie, DUNOGEANT, Laetitia, DURANT, Cécile, DUREL, Cécile-Audrey, DURIEU, Isabelle, EBOUE, Florence, Elefant, Elisabeth, FAIN, Olivier, FAUTREL, Bruno, FLIPO, René-Marc, FRAZIER, Aline, FROISSART, Antoine, GEORGIN-LAVIALLE, Sophie, GERVAIS, Elisabeth, GODEAU, Bertrand, Goffinet, François, GOMPEL, Anne, GOSSEC, Laure, GOUPILLE, Philippe, GRANGE, Claire, GUILLAUD-DANIS, Constance, HACHULLA, Eric, HOEFSLOOT, Sabine, HUMMEL, Aurélie, JEGO, Patrick, JOBARD, Stéphanie, JOSSELIN-MAHR, Laurence, LAMBERT, Marc, LANGLOIS, Vincent, LARIVIERE, Delphine, LARROCHE, Claire, LATOURTE, Augustin, LAVIGNE, Christian, LE GALLOU, Thomas, LEROUX, Gaëlle, LETAROUILLY, Jean Guillaume, LIOTÉ, Frédéric, Loeuillet, Laurence, London, Jonathan, Loustau, Valentine, LOZAC'H, Pierre, MAHEU, Emmanuel, MAILLARD, Hélène, MAROTTE, Hubert, MASSEAU, Agathe, MEKINIAN, Arsène, Melboucy Belkhir, Sara, Miceli-Richard, Corinne, MICHAUD, Martin, MICHEL, Marc, MORANNE, Olivier, MORATI-HAFSAOUI, Chafika, MOULIS, Guillaume, MOUTHON, Luc, NICOLAS, Barbara, Nizard, Jacky, ORA, Jérémy, OUTH, Rodérau, PASQUIER, Elisabeth, PENNAFORTE, Jean-Loup, PERLAT, Antoinette, PETIT-BAUER, Hélène, PILLEBOUT, Evangeline, PIOT, Jean-Maxime, PORTIER, Agnès, Pourrat, Olivier, PUECHAL, Xavier, PUGNET, Gregory, REDONDIN, Manon, REGENT, Alexis, RORIZ, Mélanie, SAILLER, Laurent, SAVEY, Léa, SCHERLINGER, Marc, SCHLEINITZ, Nicolas, Sellam, Jérémie, Sentilhes, Loïc, SERVAIS, Aude, SMETS, Perrine, SORDET, Christelle, SOUBRIER, Martin, STANKOVIC-STOJANOVIC, Katia, URBANSKI, Geoffrey, VEIT, Véronique, WEBER, Emmanuelle, YELNIK, Cécile, de Frémont, Grégoire Martin, Costedoat-Chalumeau, Nathalie, Lazaro, Estibaliz, Belkhir, Rakiba, Guettrot-Imbert, Gaëlle, Morel, Nathalie, Nocturne, Gaétane, Molto, Anna, Goulenok, Tiphaine, Diot, Elisabeth, Perard, Laurent, Ferreira-Maldent, Nicole, Le Besnerais, Maelle, Limal, Nicolas, Martis, Nihal, Abisror, Noémie, Debouverie, Odile, Richez, Christophe, Sobanski, Vincent, Maurier, François, Sauvetre, Gaëtan, Levesque, Hervé, Timsit, Marie-Agnès, Tieulié, Nathalie, Orquevaux, Pauline, Bienvenu, Boris, Mahevas, Matthieu, Papo, Thomas, Lartigau-Roussin, Céline, Chauvet, Elodie, Berthoux, Emilie, Sarrot-Reynauld, Françoise, Raffray, Loïc, Couderc, Marion, Silva, Nicolas Martin, Jourde-Chiche, Noémie, Belhomme, Nicolas, Thomas, Thierry, Poindron, Vincent, Queyrel-Moranne, Viviane, Delforge, Juliette, Le Ray, Camille, Pannier, Emmanuelle, Mariette, Xavier, Le Guern, Véronique, and Seror, Raphaèle

Published
2023
Full Text
View/download PDF

8. 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis

Author

Wendling, Daniel, Hecquet, Sophie, Fogel, Olivier, Letarouilly, Jean-Guillaume, Verhoeven, Frank, Pham, Thao, Prati, Clément, Molto, Anna, Goupille, Philippe, Dernis, Emmanuelle, Saraux, Alain, Ruyssen-Witrand, Adeline, Lukas, Cédric, Miceli-Richard, Corinne, Hudry, Christophe, Richette, Pascal, Breban, Maxime, Gossec, Laure, Dougados, Maxime, and Claudepierre, Pascal

Published
2022
Full Text
View/download PDF

9. Actualisation 2022 des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite, incluant le rhumatisme psoriasique

Author

Wendling, Daniel, Hecquet, Sophie, Fogel, Olivier, Letarouilly, Jean-Guillaume, Verhoeven, Frank, Pham, Thao, Prati, Clément, Molto, Anna, Goupille, Philippe, Dernis, Emmanuelle, Saraux, Alain, Ruyssen-Witrand, Adeline, Lukas, Cédric, Miceli-Richard, Corinne, Hudry, Christophe, Richette, Pascal, Breban, Maxime, Gossec, Laure, Dougados, Maxime, and Claudepierre, Pascal

Published
2022
Full Text
View/download PDF

11. Dietary recommendations of the French Society for Rheumatology for patients with chronic inflammatory rheumatic diseases

Author

Daien, Claire, Czernichow, Sébastien, Letarouilly, Jean-Guillaume, Nguyen, Yann, Sanchez, Pauline, Sigaux, Johanna, Beauvais, Catherine, Desouches, Sandra, Le Puillandre, Robert, Rigalleau, Vincent, Rivière, Pauline, Romon, Monique, Semerano, Luca, Seror, Raphaèle, Sfedj, Sylvie, Tournadre, Anne, Vacher, Danielle, Wendling, Daniel, Flipo, René-Marc, and Sellam, Jérémie

Published
2022
Full Text
View/download PDF

12. Recommandations de la Société française de rhumatologie sur l’alimentation des patients ayant un rhumatisme inflammatoire chronique

Author

Daien, Claire, Czernichow, Sébastien, Letarouilly, Jean-Guillaume, Nguyen, Yann, Sanchez, Pauline, Sigaux, Johanna, Beauvais, Catherine, Desouches, Sandra, Le Puillandre, Robert, Rigalleau, Vincent, Rivière, Pauline, Romon, Monique, Semerano, Luca, Seror, Raphaèle, Sfedj, Sylvie, Tournadre, Anne, Vacher, Danielle, Wendling, Daniel, Flipo, René-Marc, and Sellam, Jérémie

Published
2022
Full Text
View/download PDF

16. Evaluation globale standardisée systématique des rhumatismes inflammatoires chroniques: intérêts et limites

Author

Fogel, Olivier, primary, Portillo, Damien Caillet, additional, Najm, Aurélie, additional, Baillet, Athan, additional, Claudepierre, Pascal, additional, Conort, Ornella, additional, Dernis, Emmanuelle, additional, Fayet, Françoise, additional, Gossec, Laure, additional, Goupille, Philippe, additional, Hudry, Christophe, additional, Letarouilly, Jean-Guillaume, additional, Lukas, Cédric, additional, Marotte, Hubert, additional, Molto, Anna, additional, Pouplin, Sophie, additional, Senbel, Eric, additional, Sordet, Christelle, additional, Tournadre, Anne, additional, Truchetet, Marie-Elise, additional, Wendling, Daniel, additional, Witrand, Adeline Ruyssen, additional, and Dougados, Maxime, additional

Published
2024
Full Text
View/download PDF

22. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis.

Author

Damart, Julien, Filippou, Georgios, Andrès, Mariano, Cipolletta, Edoardo, Sirotti, Silvia, Carboni, Davide, Filippucci, Emilio, Diez, Pilar, Abhishek, Abhishek, Latourte, Augustin, Ea, Hang-Korng, Ottaviani, Sébastien, Letarouilly, Jean-Guillaume, Desbarbieux, Renaud, Graf, Sahara, Norberciak, Laurène, Richette, Pascal, and Pascart, Tristan

Subjects
BIOTHERAPY, ARTHRITIS diagnosis, DRUG therapy for arthritis, DRUG efficacy, ADRENOCORTICAL hormones, INFLAMMATION, TOCILIZUMAB, RETROSPECTIVE studies, CHONDROCALCINOSIS, TREATMENT effectiveness, METHOTREXATE, DESCRIPTIVE statistics, COLCHICINE, HYDROXYCHLOROQUINE, PATIENT safety, OFF-label use (Drugs), LONGITUDINAL method, EVALUATION
Abstract

Objectives Very little is known on the efficacy and safety of drugs for the management of chronic calcium pyrophosphate (CPP) crystal inflammatory arthritis. The objectives of this work were to describe the drugs used in the management of chronic CPP crystal inflammatory arthritis in expert European centres, and to examine treatment retention. Methods This was a retrospective cohort study. Charts from patients with a diagnosis of persistent inflammatory and/or recurrent acute CPP crystal arthritis were reviewed in seven European centres. Baseline characteristics were collected, and visits at months 3, 6, 12 and 24 included an assessment of treatment response and safety. Results One hundred and ninety-four treatments were initiated in 129 patients. Colchicine (used first-line in n  = 73/86), methotrexate (used first-line in n  = 14/36), anakinra (n  = 27) and tocilizumab (n  = 25) were the most prescribed treatments, while long-term corticosteroids, hydroxychloroquine, canakinumab and sarilumab were used occasionally. The 24-month on-drug retention was higher for tocilizumab (40%) than anakinra (18.5%) (P  < 0.05), while the difference between colchicine (29.1%) and methotrexate (44.4%) was not statistically significant (P  = 0.10). Adverse events led to 14.1% of colchicine discontinuations (100% of diarrhoea), 4.3% for methotrexate, 31.8% for anakinra and 20% for tocilizumab; all other discontinuations were related to insufficient response or losses to follow-up. Efficacy outcomes did not differ significantly between treatments throughout follow-up. Conclusion Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis

Author

Damart, Julien, primary, Filippou, Georgios, additional, Andrès, Mariano, additional, Cipolletta, Edoardo, additional, Sirotti, Silvia, additional, Carboni, Davide, additional, Filippucci, Emilio, additional, Diez, Pilar, additional, Abhishek, Abhishek, additional, Latourte, Augustin, additional, Ea, Hang-Korng, additional, Ottaviani, Sébastien, additional, Letarouilly, Jean-Guillaume, additional, Desbarbieux, Renaud, additional, Graf, Sahara, additional, Norberciak, Laurène, additional, Richette, Pascal, additional, and Pascart, Tristan, additional

Published
2023
Full Text
View/download PDF

24. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study

Author

de Frémont, Grégoire Martin, primary, Costedoat-Chalumeau, Nathalie, additional, Lazaro, Estibaliz, additional, Belkhir, Rakiba, additional, Guettrot-Imbert, Gaëlle, additional, Morel, Nathalie, additional, Nocturne, Gaétane, additional, Molto, Anna, additional, Goulenok, Tiphaine, additional, Diot, Elisabeth, additional, Perard, Laurent, additional, Ferreira-Maldent, Nicole, additional, Le Besnerais, Maelle, additional, Limal, Nicolas, additional, Martis, Nihal, additional, Abisror, Noémie, additional, Debouverie, Odile, additional, Richez, Christophe, additional, Sobanski, Vincent, additional, Maurier, François, additional, Sauvetre, Gaëtan, additional, Levesque, Hervé, additional, Timsit, Marie-Agnès, additional, Tieulié, Nathalie, additional, Orquevaux, Pauline, additional, Bienvenu, Boris, additional, Mahevas, Matthieu, additional, Papo, Thomas, additional, Lartigau-Roussin, Céline, additional, Chauvet, Elodie, additional, Berthoux, Emilie, additional, Sarrot-Reynauld, Françoise, additional, Raffray, Loïc, additional, Couderc, Marion, additional, Silva, Nicolas Martin, additional, Jourde-Chiche, Noémie, additional, Belhomme, Nicolas, additional, Thomas, Thierry, additional, Poindron, Vincent, additional, Queyrel-Moranne, Viviane, additional, Delforge, Juliette, additional, Le Ray, Camille, additional, Pannier, Emmanuelle, additional, Mariette, Xavier, additional, Le Guern, Véronique, additional, Seror, Raphaèle, additional, AUDEMARD-VERGER, Alexandra, additional, AZZI, Emmanuel, additional, BANNEVILLE, Béatrice, additional, BAUDET, Antoine, additional, BEAUDOUIN BAZIRE, Constance, additional, BELIZNA, Cristina, additional, Belot, Alexandre, additional, BENHAMOU, Ygal, additional, Berezné, Alice, additional, BERNARD-GUERVILLY, Fanny, additional, BERTHIER, Sabine, additional, BEZANAHARY, Holy, additional, BIALE, Lisa, additional, BIGOT, Adrien, additional, BLANCHARD-DELAUNAY, Claire, additional, CALAS, Anne, additional, CAMPAGNE, Julien, additional, CATHEBRAS, Pascal, additional, CAZALETS, Claire, additional, CHAIGNE, Benjamin, additional, CHANDESRIS, Olivia, additional, CHATELAIS, Jérémy, additional, CHATELUS, Emmanuel, additional, COHEN, Fleur, additional, Combe, Bernard, additional, COMPARON, Céline, additional, COQUERELLE, Pascal, additional, DAMIAN, Louise, additional, DAUGAS, Eric, additional, DE MENTHON, Mathilde, additional, DE MOREUIL, Claire, additional, DELATTRE, Estelle, additional, DELLAL, Azeddine, additional, Deneux-Tharaux, Catherine, additional, DENIS, Amélie, additional, DEPROUW, Camille, additional, DERNIS, Emmanuelle, additional, DEROUX, Alban, additional, DESOUCHES, Sandra, additional, Dieudé, Philippe, additional, DIREZ, Guillaume, additional, Dougados, Maxime, additional, DRIESSEN, Marine, additional, DU THANH, Aurélie, additional, DUNOGEANT, Laetitia, additional, DURANT, Cécile, additional, DUREL, Cécile-Audrey, additional, DURIEU, Isabelle, additional, EBOUE, Florence, additional, Elefant, Elisabeth, additional, FAIN, Olivier, additional, FAUTREL, Bruno, additional, FLIPO, René-Marc, additional, FRAZIER, Aline, additional, FROISSART, Antoine, additional, GEORGIN-LAVIALLE, Sophie, additional, GERVAIS, Elisabeth, additional, GODEAU, Bertrand, additional, Goffinet, François, additional, GOMPEL, Anne, additional, GOSSEC, Laure, additional, GOUPILLE, Philippe, additional, GRANGE, Claire, additional, GUILLAUD-DANIS, Constance, additional, HACHULLA, Eric, additional, HOEFSLOOT, Sabine, additional, HUMMEL, Aurélie, additional, JEGO, Patrick, additional, JOBARD, Stéphanie, additional, JOSSELIN-MAHR, Laurence, additional, LAMBERT, Marc, additional, LANGLOIS, Vincent, additional, LARIVIERE, Delphine, additional, LARROCHE, Claire, additional, LATOURTE, Augustin, additional, LAVIGNE, Christian, additional, LE GALLOU, Thomas, additional, LEROUX, Gaëlle, additional, LETAROUILLY, Jean Guillaume, additional, LIOTÉ, Frédéric, additional, Loeuillet, Laurence, additional, London, Jonathan, additional, Loustau, Valentine, additional, LOZAC'H, Pierre, additional, MAHEU, Emmanuel, additional, MAILLARD, Hélène, additional, MAROTTE, Hubert, additional, MASSEAU, Agathe, additional, MEKINIAN, Arsène, additional, Melboucy Belkhir, Sara, additional, Miceli-Richard, Corinne, additional, MICHAUD, Martin, additional, MICHEL, Marc, additional, MORANNE, Olivier, additional, MORATI-HAFSAOUI, Chafika, additional, MOULIS, Guillaume, additional, MOUTHON, Luc, additional, NICOLAS, Barbara, additional, Nizard, Jacky, additional, ORA, Jérémy, additional, OUTH, Rodérau, additional, PASQUIER, Elisabeth, additional, PENNAFORTE, Jean-Loup, additional, PERLAT, Antoinette, additional, PETIT-BAUER, Hélène, additional, PILLEBOUT, Evangeline, additional, PIOT, Jean-Maxime, additional, PORTIER, Agnès, additional, Pourrat, Olivier, additional, PUECHAL, Xavier, additional, PUGNET, Gregory, additional, REDONDIN, Manon, additional, REGENT, Alexis, additional, RORIZ, Mélanie, additional, SAILLER, Laurent, additional, SAVEY, Léa, additional, SCHERLINGER, Marc, additional, SCHLEINITZ, Nicolas, additional, Sellam, Jérémie, additional, Sentilhes, Loïc, additional, SERVAIS, Aude, additional, SMETS, Perrine, additional, SORDET, Christelle, additional, SOUBRIER, Martin, additional, STANKOVIC-STOJANOVIC, Katia, additional, URBANSKI, Geoffrey, additional, VEIT, Véronique, additional, WEBER, Emmanuelle, additional, and YELNIK, Cécile, additional

Published
2023
Full Text
View/download PDF

25. Évaluation de l'effet du tofacitinib sur les tissus osseux et adipeux dans la polyarthrite rhumatoïde

Author

Letarouilly, Jean-Guillaume, Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 (MABLab (ex-pmoi)), Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Lille, Julien Paccou, and Aline Clabaut

Subjects
Adipose tissue, Tissus adipeux, Body composition, Adiposité, Polyarthrite rhumatoïde, Inhibiteur des janus kinases, Tofacitinib, Bone mineral density, Adipocytes, Rheumatoid arthritis, Janus kinases inhibitors, Densitométrie osseuse, Composition corporelle, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Adiposity
Abstract

Background: Systemic inflammation is the main factor underlying secondary osteoporosis and cardiovascular risk in patients with rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi), such as tofacitinib (Tofa), can control systemic inflammation and may have beneficial effects on bone in various models. This might be due to direct effects on the bone microenvironment and not exclusively based on their anti-inflammatory function. Bone marrow adipocytes (BMAds) are abundant in the bone microenvironment. The effect of JAKi on BMAds is unknown, but evidence suggests that there is competition between human bone marrow-derived stromal cell (hBMSCs) differentiation routes towards BMAds and osteoblasts (Ob) in osteoporosis. JAKi could also have an impact on the visceral adiposity which is associated with the cardiovascular risk.Objectives: The aims of the first part of the PhD were to determine whether Tofa influences BMAds, and Ob derived from hBMSCs and to investigate the potential effects of Tofa on body composition, on bone marrow adipose tissue (BMAT) and bone mineral density (BMD) in RA patients. The aims of the second part of the PhD were to determine the impact of RA on body composition, BMD and BMAT.Methods: To determine the effect of Tofa on cellular commitment, hBMSCs were differentiated to BMAds or Ob for 3 days together with Tofa at 200, 400, or 800 nM and TNFα. This study was also conducted using differentiated BMAds. The impact of Tofa was determined by gene and protein expression analysis and cell density monitoring. In parallel, in a pilot study of 9 RA patients treated with Tofa 5 mg twice a day (NCT04175886), the proton density fat fraction (PDFF) was measured using MRI at the lumbar spine at baseline and at 6 months. The ongoing RAFAT study (NCT05269069) is a case-control study including healthy volunteers matched for sex, age, body mass index, and menopausal status with RA patients.Results: In non-inflammatory conditions, the gene expression of Runx2 and Dlx5 decreased in Ob treated with Tofa (p

Published
2023

26. Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings

Author

Philippoteaux, Cécile, primary, Deprez, Valentine, additional, Nottez, Aurore, additional, Cailliau, Emeline, additional, Houvenagel, Eric, additional, Deprez, Xavier, additional, Philippe, Peggy, additional, Pascart, Tristan, additional, Flipo, René-Marc, additional, Goëb, Vincent, additional, and Letarouilly, Jean-Guillaume, additional

Published
2022
Full Text
View/download PDF

30. Erratum to “2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis” [Joint Bone Spine 2022;89:105344]

Author

Wendling, Daniel, primary, Hecquet, Sophie, additional, Fogel, Olivier, additional, Letarouilly, Jean-Guillaume, additional, Verhoeven, Frank, additional, Pham, Thao, additional, Prati, Clément, additional, Molto, Anna, additional, Goupille, Philippe, additional, Dernis, Emmanuelle, additional, Saraux, Alain, additional, Ruyssen-Witrand, Adeline, additional, Lukas, Cédric, additional, Miceli-Richard, Corinne, additional, Hudry, Christophe, additional, Richette, Pascal, additional, Breban, Maxime, additional, Gossec, Laure, additional, Dougados, Maxime, additional, and Claudepierre, Pascal, additional

Published
2022
Full Text
View/download PDF

31. Stimulatory Effect of Tofacitinib on Bone Marrow Adipocytes Differentiation

Author

Letarouilly, Jean-Guillaume, Paccou, Julien, Badr, Sammy, Chauveau, Christophe, Broux, Odile, Clabaut-Caruso, Aline, Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 (MABLab (ex-pmoi)), and Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
rheumatoid arthritis, tofacitinib, human bone marrow-derived stromal cells, [SDV]Life Sciences [q-bio], bone marrow adipocytes, osteoblasts, differentiation
Abstract

International audience; Background: Systemic inflammation is the main factor underlying secondary osteoporosis in patients with rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi), such as tofacitinib (Tofa), can control systemic inflammation and may have beneficial effects on bone in various models. This might be due to direct effects on the bone microenvironment and not exclusively based on their anti-inflammatory function. Bone marrow adipocytes (BMAds) are abundant in the bone microenvironment. The effect of JAKi on BMAds is unknown, but evidence suggests that there is competition between human bone marrow-derived stromal cell (hBMSC) differentiation routes towards BMAds and osteoblasts (Ob) in osteoporosis. Objectives: The aims of the study are to determine whether Tofa influences BMAds and Ob derived from hBMSCs and to investigate the potential effects of Tofa on bone marrow adiposity in RA patients. Methods: To determine the effect of Tofa on cellular commitment, hBMSCs were differentiated to BMAds or OBs for 3 days together with Tofa at 200, 400, or 800 nM and TNFa. This study was also conducted using differentiated BMAds. The impact of Tofa was determined by gene and protein expression analysis and cell density monitoring. In parallel, in a pilot study of 9 RA patients treated with Tofa 5 mg twice a day (NCT04175886), the proton density fat fraction (PDFF) was measured using MRI at the lumbar spine at baseline and at 6 months. Results: In non-inflammatory conditions, the gene expression of Runx2 and Dlx5 decreased in Ob treated with Tofa (p

Published
2022
Full Text
View/download PDF

32. Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis.

Author

Letarouilly, Jean-Guillaume, Vermersch, Patrick, and Flipo, René-Marc

Subjects
*DRUG therapy for rheumatism, *MULTIPLE sclerosis, *ANTI-inflammatory agents, *ANTIRHEUMATIC agents, *COMORBIDITY, *PHARMACODYNAMICS
Abstract

Dealing with patients with both multiple sclerosis (MS) and inflammatory rheumatic disorders (IRDs) is not uncommon for a rheumatologist, as there is a statistical association between SpA and MS. As several CNS demyelinating events have been reported in patients treated with TNF inhibitor (TNFi), the pre-existing demyelinating disease was considered a contraindication for TNFi. However, this contraindication is mainly based on a randomized controlled trial in MS and not on large epidemiological studies. According to the last epidemiological studies, TNFi might not be an inducer of MS. Moreover, there are no clear recommendations on the use of the other DMARDs in patients suffering from an IRD and MS. In this review, we summarize the link between MS and IRDs and the impact of DMARDs on MS, especially TNFi. We also look at the impact of disease-modifying drugs for adults with MS and IRDs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Additional file 9 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Subjects
food and beverages, lipids (amino acids, peptides, and proteins), eye diseases
Abstract

Additional file 9. Forest plot of effect of oral PUFA supplementation on patient-reported pain (VAS) in RA.

Published
2022
Full Text
View/download PDF

37. Additional file 16 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Abstract

Additional file 16. Funnel plots of publication bias.

Published
2022
Full Text
View/download PDF

38. Additional file 4 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Abstract

Additional file 4. Population baseline characteristics of studies included in the meta-analysis.

Published
2022
Full Text
View/download PDF

39. Additional file 6 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Subjects
musculoskeletal diseases, food and beverages, lipids (amino acids, peptides, and proteins), human activities, eye diseases
Abstract

Additional file 6. Forest plot of effect of oral PUFA supplementation on tender joint count in RA.

Published
2022
Full Text
View/download PDF

40. Additional file 5 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Subjects
musculoskeletal diseases, food and beverages, lipids (amino acids, peptides, and proteins), skin and connective tissue diseases, eye diseases
Abstract

Additional file 5. Effect of PUFA supplementation compared to control on parameters of rheumatoid arthritis.

Published
2022
Full Text
View/download PDF

41. Additional file 2 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Abstract

Additional file 2. Characteristics of studies not included in the meta-analysis by source of PUFA.

Published
2022
Full Text
View/download PDF

42. Additional file 3 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Subjects
education
Abstract

Additional file 3. Risk of bias according to the Cochrane Collaboration Risk of Bias tool.

Published
2022
Full Text
View/download PDF

43. Additional file 7 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Subjects
food and beverages, lipids (amino acids, peptides, and proteins), eye diseases
Abstract

Additional file 7. Forest plot of effect of oral PUFA supplementation on swollen joint count in RA.

Published
2022
Full Text
View/download PDF

44. Additional file 8 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis

Author

Sigaux, Johanna, Mathieu, Sylvain, Nguyen, Yann, Sanchez, Pauline, Letarouilly, Jean-Guillaume, Soubrier, Martin, Czernichow, Sébastien, Flipo, René-Marc, Sellam, Jérémie, and Daïen, Claire

Subjects
musculoskeletal diseases, animal structures, food and beverages, lipids (amino acids, peptides, and proteins), eye diseases
Abstract

Additional file 8. Forest plot of effect of oral PUFA supplementation on morning stiffness duration in RA.

Published
2022
Full Text
View/download PDF

46. Self-reported Impact of the Early 2020 COVID-19 Crisis on the Healthcare Pathway During and After Lockdown in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Practical Survey

Author

Nasseh, Jessica, primary, Podevin, Céline, additional, Ternynck, Camille, additional, Zephir, Hélène, additional, Letarouilly, Jean-Guillaume, additional, Flipo, René-Marc, additional, Nachury, Maria, additional, Chenivesse, Cécile, additional, Hachulla, Eric, additional, Launay, David, additional, Staumont-Salle, Delphine, additional, and Dezoteux, Frédéric, additional

Published
2022
Full Text
View/download PDF

47. Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings.

Author

Philippoteaux, Cécile, Deprez, Valentine, Nottez, Aurore, Cailliau, Emeline, Houvenagel, Eric, Deprez, Xavier, Philippe, Peggy, Pascart, Tristan, Flipo, René-Marc, Goëb, Vincent, and Letarouilly, Jean-Guillaume

Subjects
RHEUMATOID arthritis, THROMBOEMBOLISM, KINASE inhibitors, BARICITINIB, WARNINGS, ABATACEPT
Abstract

Background: Baricitinib (BARI) or Tofacitinib (TOFA) were the first Janus Kinase Inhibitors (JAKi) to be marketed in rheumatoid arthritis (RA). Concerns regarding venous thromboembolism (VTE) risk have emerged during the past years. The aim of the study was to compare the baseline characteristics of patients initiating BARI or TOFA in RA before versus after European Medicine Agency (EMA)'s VTE warnings and to compare real-world persistence with these two drugs. Methods: In this multicentric cohort study, RA patients initiating BARI or TOFA were included from October 2017, date of BARI marketing authorization in France, to September 2020. Baseline characteristics regarding VTE risk were compared (before vs. after May 2019) by using pre-specified statistical tests. Comparison of persistence was assessed by using propensity-score methods. Results: 232 patients were included; 155 with BARI and 77 with TOFA. Baseline characteristics of patients regarding VTE risk factors were not statistically different when Janus Kinase inhibitor (JAKi) was initiated before vs. after EMA's warnings although a trend towards a lower proportion of VTE history was observed. Five VTE events occurred, four with BARI, one with TOFA. Cumulative persistence rate at 2 years was similar between BARI and TOFA: HR 0.96; 95% Cl: 0.52 to 1.74; p = 0.89. Conclusions: Our study did not show a significant change in patients characteristics starting a JAKi after the EMA's warnings, probably due to a lack of power. Though, the lower proportion of VTE history in patients after May 2019 suggests that rheumatologists have taken into account the potential VTE risk. These results need to be confirmed by further evidence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis

Author

Sigaux, Johanna, primary, Mathieu, Sylvain, additional, Nguyen, Yann, additional, Sanchez, Pauline, additional, Letarouilly, Jean-Guillaume, additional, Soubrier, Martin, additional, Czernichow, Sébastien, additional, Flipo, René-Marc, additional, Sellam, Jérémie, additional, and Daïen, Claire, additional

Published
2021
Full Text
View/download PDF

49. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study

Author

Letarouilly, Jean-Guillaume, primary, Pham, Thao, additional, Pierache, Adeline, additional, Acquacalda, Émilie, additional, Banneville, Béatrice, additional, Barbarot, Sébastien, additional, Baudart, Pauline, additional, Bauer, Élodie, additional, Claudepierre, Pascal, additional, Constantin, Arnaud, additional, Dernis, Emmanuelle, additional, Felten, Renaud, additional, Gaudin, Philippe, additional, Girard, Céline, additional, Gombert, Bruno, additional, Goupille, Philippe, additional, Guennoc, Xavier, additional, Henry-Desailly, Isabelle, additional, Jullien, Denis, additional, Karimova, Elena, additional, Lanot, Sylvain, additional, Le Dantec, Loïc, additional, Pascart, Tristan, additional, Plastaras, Laurianne, additional, Sultan, Nathalie, additional, Truchet, Xavier, additional, Varin, Stéphane, additional, Wendling, Daniel, additional, Gaboriau, Louise, additional, Staumont-Sallé, Delphine, additional, Peyrin-Biroulet, Laurent, additional, and Flipo, René-Marc, additional

Published
2021
Full Text
View/download PDF

50. sj-pdf-2-tab-10.1177_1759720X211015006 – Supplemental material for Body composition in patients with rheumatoid arthritis: a narrative literature review

Author

Letarouilly, Jean-Guillaume, Flipo, René-Marc, Cortet, Bernard, Tournadre, Anne, and Paccou, Julien

Subjects
body regions, FOS: Clinical medicine, 110604 Sports Medicine, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110314 Orthopaedics
Abstract

Supplemental material, sj-pdf-2-tab-10.1177_1759720X211015006 for Body composition in patients with rheumatoid arthritis: a narrative literature review by Jean-Guillaume Letarouilly, René-Marc Flipo, Bernard Cortet, Anne Tournadre and Julien Paccou in Therapeutic Advances in Musculoskeletal Disease

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results